<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04715113</url>
  </required_header>
  <id_info>
    <org_study_id>2020-02163_A4</org_study_id>
    <nct_id>NCT04715113</nct_id>
  </id_info>
  <brief_title>Blood Markers Predict Effect of Normobaric Hypoxia at Rest and During Exercise in Patients With Pulmonary Hypertension</brief_title>
  <acronym>HEXABM</acronym>
  <official_title>Hemodynamic Effects of Acute Normobaric Hypoxia During Exercise in Patients With Pulmonary Hypertension: Single-center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of acute normobaric hypoxia during exercise in patients with pulmonary&#xD;
      hypertension on blood markers (serum markers of iron and red blood cell homeostasis and&#xD;
      micro-RNAs known to be associated with PH).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum levels of ferritin</measure>
    <time_frame>Baseline</time_frame>
    <description>Analyis of serum levels of ferritin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum levels of transferrin</measure>
    <time_frame>Baseline</time_frame>
    <description>Analyis of serum levels of transferrin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of total iron</measure>
    <time_frame>Baseline</time_frame>
    <description>Analysis of serum levels of total iron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of erythropoietin</measure>
    <time_frame>Baseline</time_frame>
    <description>Analysis of serum levels of erythropoietin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of Erythroferrone</measure>
    <time_frame>Baseline</time_frame>
    <description>Analysis of serum levels of erythroferrone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of hepcidin</measure>
    <time_frame>Baseline</time_frame>
    <description>Analysis of serum levels of hepcidin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>micro-RNA levels</measure>
    <time_frame>Baseline</time_frame>
    <description>Analysis of micro-RNA levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Normobaric hypoxia (FiO2 15%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of deoxygenated air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-ambient air (FiO2 21%)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Inhalation of room air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normobaric hypoxia (FiO2 15%) under Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhalation of deoxygenated air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-ambient air (FiO2 21%) under Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhalation of room air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normobaric hypoxia (FiO2 15%)</intervention_name>
    <description>Inhalation of deoxygenated air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
    <arm_group_label>Normobaric hypoxia (FiO2 15%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-ambient air (FiO2 21%)</intervention_name>
    <description>Inhalation of room air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise.</description>
    <arm_group_label>Placebo-ambient air (FiO2 21%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normobaric hypoxia (FiO2 15%) under Sildenafil</intervention_name>
    <description>Inhalation of deoxygenated air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil.</description>
    <arm_group_label>Normobaric hypoxia (FiO2 15%) under Sildenafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo-ambient air (FiO2 21%) under Sildenafil</intervention_name>
    <description>Inhalation of room air through an altitude simulator (&quot;Altitrainer&quot;), for approx. 1/2 hour given by a facemask, first at rest and then during exercise under Sildenafil.</description>
    <arm_group_label>Placebo-ambient air (FiO2 21%) under Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
          -  PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary&#xD;
             artery pressure &gt;20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary&#xD;
             arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic&#xD;
             right-heart catheterization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  resting partial pressure of oxygen &lt;8 kilopascal at Zürich altitude on ambient air&#xD;
&#xD;
          -  exposure to an altitude &gt;1000 m for ≥3 nights during the last 2 weeks before the study&#xD;
&#xD;
          -  inability to follow the procedures of the study&#xD;
&#xD;
          -  patients who take nitrates&#xD;
&#xD;
          -  other clinically significant concomitant end-stage disease (e.g., renal failure,&#xD;
             hepatic dysfunction)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversityHospital Zurich, Department of Pulmonology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Ulrich, Prof. Dr.</last_name>
    <phone>+41442552220</phone>
    <email>silvia.ulrich@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saxer Stéphanie, Dr.</last_name>
    <phone>+41442552248</phone>
    <email>stephanie.saxer@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia o Ulrich, Prof. Dr.</last_name>
      <phone>+41442552220</phone>
      <email>silvia.ulrich@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypoxia</keyword>
  <keyword>exercise</keyword>
  <keyword>blood markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share individual participant data after publication of the manuscript. The decision about the platform is ongoing.</ipd_description>
    <ipd_time_frame>After publication of the manuscript</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

